Related Experiment Videos
Improved morbidity with the use of nasal continuous positive airway pressure in I-cell disease
1Division of Pediatric Pulmonary Medicine, Children's Medical Center of Brooklyn, SUNY, New York, USA.
Insights
Nasal continuous positive airway pressure (NCPAP) significantly reduced hospitalizations and improved breathing in a child with I-cell disease and obstructive sleep apnea. This treatment can lessen illness and enhance life quality for these patients.
Area of Science:
- Medical Science
- Pediatrics
- Respiratory Medicine
Background:
- I-cell disease (mucolipidosis II) causes severe health issues, including failure to thrive and respiratory infections, often leading to early death.
- Obstructive sleep apnea (OSA) is a common complication in I-cell disease, exacerbated by craniofacial anomalies and upper respiratory infections, significantly increasing patient morbidity.
Observation:
- A 2-year-old girl with I-cell disease, OSA, and craniofacial anomalies was treated with nasal continuous positive airway pressure (NCPAP) for six months.
- The treatment involved continuous positive airway pressure delivered via nasal mask.
Findings:
- NCPAP therapy resulted in a notable reduction in hospitalizations due to respiratory problems.
- Significant improvements in arterial blood gas levels were observed during NCPAP use.
- The study highlights the link between anatomical defects, OSA, and respiratory morbidity in I-cell disease.
Implications:
- NCPAP can be an effective intervention for managing obstructive sleep apnea in patients with I-cell disease.
- Implementing NCPAP may lead to decreased morbidity and improved quality of life for individuals with this rare genetic disorder.
- Further research into respiratory support strategies for I-cell disease patients is warranted.
Abstract:
Patients with I-cell disease (mucolipidosis II) present with progressive morbidity failure to thrive, cardiomegaly, and recurrent respiratory tract infections leading to progressive deterioration and early death. We evaluated use of nasal continuous positive airway pressure (NCPAP) for 6 months in a 2-year-old girl with I-cell disease, obstructive sleep apnea (OSA), and craniofacial anomalies. We observed a marked decrease in hospitalizations for respiratory problems and a marked improvement in arterial blood gases with the use of NCPAP. In patients with I-cell disease, anatomical defects with superimposed upper respiratory tract infections cause worsening of OSA, and OSA contributes significantly to morbidity. In such patients NCPAP can lessen morbidity and can improve the quality of life.